The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Ongoing MDS clinical trials to look out for
Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, comments on novel treatments targeting myelodysplastic syndromes (MDS) under development including pevonedistat, a NEDD8-activating enzyme (NAE) inhibitor, and sabatolimab, an anti-TIM-3 antibody. Dr Pollyea additionally highlights venetoclax and magrolimab, anti-CD47 monoclonal antibody, which are both undergoing clinical trials. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
